These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)]. Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998 [TBL] [Abstract][Full Text] [Related]
3. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249 [TBL] [Abstract][Full Text] [Related]
4. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR Clin Infect Dis; 2004 Sep; 39(5):641-8. PubMed ID: 15356776 [TBL] [Abstract][Full Text] [Related]
5. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L; Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662 [TBL] [Abstract][Full Text] [Related]
6. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Motlova J; Benes C; Kriz P Epidemiol Infect; 2009 Apr; 137(4):562-9. PubMed ID: 18796171 [TBL] [Abstract][Full Text] [Related]
7. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Lehmann D; Willis J; Moore HC; Giele C; Murphy D; Keil AD; Harrison C; Bayley K; Watson M; Richmond P Clin Infect Dis; 2010 Jun; 50(11):1477-86. PubMed ID: 20420501 [TBL] [Abstract][Full Text] [Related]
8. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165 [TBL] [Abstract][Full Text] [Related]
10. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Guevara M; Barricarte A; Gil-Setas A; García-Irure JJ; Beristain X; Torroba L; Petit A; Polo Vigas ME; Aguinaga A; Castilla J Clin Microbiol Infect; 2009 Nov; 15(11):1013-9. PubMed ID: 19673968 [TBL] [Abstract][Full Text] [Related]
11. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Weatherholtz R; Millar EV; Moulton LH; Reid R; Rudolph K; Santosham M; O'Brien KL Clin Infect Dis; 2010 May; 50(9):1238-46. PubMed ID: 20367225 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376 [TBL] [Abstract][Full Text] [Related]
13. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark. Slotved HC; Dalby T; Hoffmann S Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630 [TBL] [Abstract][Full Text] [Related]
14. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. De Wals P; Black S; Borrow R; Pearce D Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887 [TBL] [Abstract][Full Text] [Related]
15. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392 [TBL] [Abstract][Full Text] [Related]
16. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190 [TBL] [Abstract][Full Text] [Related]
17. Invasive pneumococcal disease in Fiji: clinical syndromes, epidemiology, and the potential impact of pneumococcal conjugate vaccine. Russell FM; Carapetis JR; Tikoduadua L; Paeds D; Chandra R; Seduadua A; Satzke C; Pryor J; Buadromo E; Waqatakirewa L; Mulholland EK Pediatr Infect Dis J; 2010 Sep; 29(9):870-2. PubMed ID: 20622710 [TBL] [Abstract][Full Text] [Related]
18. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956 [TBL] [Abstract][Full Text] [Related]
19. Invasive pneumococcal disease in England and Wales: vaccination implications. Sleeman K; Knox K; George R; Miller E; Waight P; Griffiths D; Efstratiou A; Broughton K; Mayon-White RT; Moxon ER; Crook DW; ; J Infect Dis; 2001 Jan; 183(2):239-246. PubMed ID: 11120930 [TBL] [Abstract][Full Text] [Related]
20. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Halasa NB; Shankar SM; Talbot TR; Arbogast PG; Mitchel EF; Wang WC; Schaffner W; Craig AS; Griffin MR Clin Infect Dis; 2007 Jun; 44(11):1428-33. PubMed ID: 17479937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]